Cargando…

Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs

An important role of the clinical toxicology laboratory is to provide continuous diagnostic testing for patients with altered mental status and for other medical indications. To meet these needs, we have developed a new Gas Chromatography-Mass Spectrometry (GC-MS) platform that facilitates routine s...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Hari, Woo, Fred, Hoofnagle, Andrew N., Baird, Geoffrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723246/
https://www.ncbi.nlm.nih.gov/pubmed/23935615
http://dx.doi.org/10.1155/2013/329407
_version_ 1782278261353480192
author Nair, Hari
Woo, Fred
Hoofnagle, Andrew N.
Baird, Geoffrey S.
author_facet Nair, Hari
Woo, Fred
Hoofnagle, Andrew N.
Baird, Geoffrey S.
author_sort Nair, Hari
collection PubMed
description An important role of the clinical toxicology laboratory is to provide continuous diagnostic testing for patients with altered mental status and for other medical indications. To meet these needs, we have developed a new Gas Chromatography-Mass Spectrometry (GC-MS) platform that facilitates routine screening and automated reporting of 212 drugs by laboratory technologists around the clock without the need to sign out by an on-site mass spectrometry-trained toxicologist. The platform uses a programmable temperature vaporizer (PTV) injector for large sample volume injection and the free software Automated Mass Spectral Deconvolution and Identification System (AMDIS) for data reduction and spectral matching that facilitates rapid library searching and analyte identification. Method comparison with 118 patient samples demonstrated that this platform and data searching algorithm independently provided improvements in sensitivity compared to an established GC-MS platform. Further examination of the role of the data processing software and the in-house databases used in the established versus the new platform demonstrated that the improved analytical sensitivity of the new platform was attributed to both the technical superiority of the new GC-MS instrumentation and the use of AMDIS in conjunction with the newly generated in-house library for data processing.
format Online
Article
Text
id pubmed-3723246
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37232462013-08-09 Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs Nair, Hari Woo, Fred Hoofnagle, Andrew N. Baird, Geoffrey S. J Toxicol Research Article An important role of the clinical toxicology laboratory is to provide continuous diagnostic testing for patients with altered mental status and for other medical indications. To meet these needs, we have developed a new Gas Chromatography-Mass Spectrometry (GC-MS) platform that facilitates routine screening and automated reporting of 212 drugs by laboratory technologists around the clock without the need to sign out by an on-site mass spectrometry-trained toxicologist. The platform uses a programmable temperature vaporizer (PTV) injector for large sample volume injection and the free software Automated Mass Spectral Deconvolution and Identification System (AMDIS) for data reduction and spectral matching that facilitates rapid library searching and analyte identification. Method comparison with 118 patient samples demonstrated that this platform and data searching algorithm independently provided improvements in sensitivity compared to an established GC-MS platform. Further examination of the role of the data processing software and the in-house databases used in the established versus the new platform demonstrated that the improved analytical sensitivity of the new platform was attributed to both the technical superiority of the new GC-MS instrumentation and the use of AMDIS in conjunction with the newly generated in-house library for data processing. Hindawi Publishing Corporation 2013 2013-07-10 /pmc/articles/PMC3723246/ /pubmed/23935615 http://dx.doi.org/10.1155/2013/329407 Text en Copyright © 2013 Hari Nair et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Nair, Hari
Woo, Fred
Hoofnagle, Andrew N.
Baird, Geoffrey S.
Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs
title Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs
title_full Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs
title_fullStr Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs
title_full_unstemmed Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs
title_short Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs
title_sort clinical validation of a highly sensitive gc-ms platform for routine urine drug screening and real-time reporting of up to 212 drugs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723246/
https://www.ncbi.nlm.nih.gov/pubmed/23935615
http://dx.doi.org/10.1155/2013/329407
work_keys_str_mv AT nairhari clinicalvalidationofahighlysensitivegcmsplatformforroutineurinedrugscreeningandrealtimereportingofupto212drugs
AT woofred clinicalvalidationofahighlysensitivegcmsplatformforroutineurinedrugscreeningandrealtimereportingofupto212drugs
AT hoofnagleandrewn clinicalvalidationofahighlysensitivegcmsplatformforroutineurinedrugscreeningandrealtimereportingofupto212drugs
AT bairdgeoffreys clinicalvalidationofahighlysensitivegcmsplatformforroutineurinedrugscreeningandrealtimereportingofupto212drugs